PBLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Parabilis Medicines, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$25.35+2.60 (+11.43%)
Close on Oct 19, 2026
- Market cap
- $732.82M
- P/E (TTM)
- –
- Dividend yield
- –
About Parabilis Medicines
Pharmaceutical Preparations, SIC 2834
Parabilis Medicines, Inc. is listed on Nasdaq under the ticker PBLS, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Parabilis Medicines, Inc.
- Headquarters
- Cambridge, MA
- Address
- 30 Acorn Park Drive, 6th Floor 02140
- Phone
- (617) 945-9510
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- PBLS
- Exchange
- Nasdaq
- IPO date
- Jun 10, 2026
- Shares outstanding
- 124M, Aug 10, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1657677
- CUSIP
- 698955101
- ISIN
- US6989551014
- EIN
- 47-4505725
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mathai Mammen | President & CEO, Director | – |
| Teresa Jurgensen | General Counsel | – |
| Helen Huei-in Ho | See Remarks | – |
| Mohammed Fawzi Benzaghou | Chief Medical Officer | – |
| Rohin Mhatre | See Remarks | – |
| Thomas Rodolpho Kotarakos | Chief Financial Officer | – |
| Craig Tendler | Director | – |
| Capital Healthcare Fund LP RA | Director | – |
| Rajeev M. Shah | Director | – |
| RA Capital Nexus Fund III, L.P. | Director | 6,556,740 |
| Peter Kolchinsky | Director | – |
| Ra Capital Management, L.P. | Director | 26,529,686 |
| Alan Sebulsky | Director | 25,935 |
| Edward M. Fitzgerald | Director | 14,688 |
| Alexis Borisy | Director | 105,414 |
| Richard Klausner | Director | – |
| Barbara Weber | Director | – |
| Jake Simson | Director | – |
| Krishna Yeshwant | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 10, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 5, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
| Dec 2, 2022 | Name change | Name changed from FOG PHARMACEUTICALS, INC. to Parabilis Medicines, Inc. |